Replaces Prod. #: BML-C115
Specific, competitive and reversible acetylcholinesterase inhibitor. Alzheimer's disease therapeutic.
Product Details
| Alternative Name: | Galantamine, Nivalin |
| |
| Formula: | C17H21NO3 . HBr |
| |
| MW: | 287.4 . 80.9 |
| |
| CAS: | 1953-04-4 |
| |
| MI: | 14: 4340 |
| |
| RTECS: | DF8075000 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white crystalline solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml) or 100% ethanol (4mg/ml); sparingly soluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Solutions are stable for up to 3 months when stored at -20°C. |
| |
| Handling: | Protect from moisture. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Xirp Proteins Mark Injured Skeletal Muscle in Zebrafish: C. Otten, et al.; PLoS One
7, e31041 (2012),
Abstract;
Full Text
Acetylcholinesterase inhibitors: novel activities of old molecules.: M. Racchi, et al.; Pharmacol. Res.
50, 441 (2004),
Abstract;
Galanthamine from snowdrop-the development of a modern drug against Alzheimer's disease from local Caucasian knowledge.: M. Heinrich & H. Lee Teoh; J. Ethnopharmacol
92, 147 (2004),
Abstract;
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats: P. Chopin & M. Briley; Psychopharmacology
106, 26 (1992),
Abstract;
Galanthamine treatment in Alzheimer's disease: P. Dal-Bianco, et al.; J. Neural. Transm. Suppl.
33, 59 (1991),
Abstract;
Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine: T. Thomsen et al.; Eur. J. Clin. Chem. Clin. Biochem.
29, 487 (1991),
Abstract;
